Impact of Pathology Review for Decision Therapy in Localized Prostate Cancer

Pedro Luiz Serrano Usón Junior¹, Ricardo Silvestre e Silva Macarenco², Fernando Nunes Oliveira¹ and Oren Smaletz¹

¹Oncology Department, Hospital Israelita Albert Einstein, São Paulo, Brazil. ²Pathology Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.

ABSTRACT

BACKGROUND: The Gleason score is an essential tool in the decision to treat localized prostate cancer. However, experienced pathologists can classify Gleason score differently than do low-volume pathologists, and this may affect the treatment decision. This study sought to assess the impact of pathology review of external biopsy specimens from 23 men with a recent diagnosis of localized prostate cancer.

METHODS: All external biopsy specimens were reviewed at our pathology department. Data were retrospectively collected from scanned charts.

RESULTS: The median patient age was 63 years (range: 46–74 years). All patients had a Karnofsky performance score of 90% to 100%. The median prostate-specific antigen level was 23.6 ng/dL (range: 1.04–13.6 ng/dL). Among the 23 reviews, the Gleason score changed for 8 (35%) patients: 7 upgraded and 1 downgraded. The new Gleason score affected the treatment decision in 5 of 8 cases (62.5%).

CONCLUSIONS: This study demonstrates the need for pathology review in patients with localized prostate cancer before treatment because Gleason score can change in more than one-third of patients and can affect treatment decision in almost two-thirds of recategorized patients.

KEYWORDS: Prostate cancer, Gleason score, pathology, prostate adenocarcinoma

RECEIVED: August 11, 2017. ACCEPTED: September 26, 2017.

PEER REVIEW: Three peer reviewers contributed to the peer review report. Reviewers’ reports totaled 293 words, excluding any confidential comments to the academic editor.

TYPE: Short Report

FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Corresponding Author: Pedro Luiz Serrano Usón Junior, Oncology Department, Hospital Israelita Albert Einstein, 627/701 Av. Albert Einstein, São Paulo 05651-901, Brazil. Email: pedroluiz_uson@hotmail.com

Introduction

Prostate adenocarcinoma is the most common cancer in men, with increasing incidence of diagnoses at earlier stages of disease in recent years, mainly due to the application of the prostate-specific antigen (PSA) test.¹

In patients with localized disease, stratification of the risk for disease progression and calculation of life expectancy are fundamental tools in choosing the appropriate treatment for each patient.² Currently, this stratification is determined from a group of factors that are based on the TNM staging of the disease, the Gleason score, and levels of PSA.³–⁵

The Gleason score is still an essential tool in the decision to start initial treatment of localized prostate cancer. However, experienced pathologists can classify Gleason score differently than do general pathologists.⁶–¹⁰

To illustrate the importance of Gleason score in low-risk patients with a Gleason score of 6 in active surveillance, Fleshner et al.¹¹ found that a repeat biopsy strategy showed a 38% score increase.

We also have evidence that the Gleason score on needle biopsy is an inexact predictor of the final score following prostatectomy, and patients with a biopsy Gleason score of 6 who are undergraded are at significantly higher risk for adverse pathological features and biochemical recurrence.¹²

In some situations, pathology review by a different pathologist results in a new score. Pathology review can affect treatment decision.

Objectives

This article assessed the impact of pathology review of external biopsy specimens from 23 men with a recent diagnosis of localized prostate cancer. These patients were evaluated at the Prostate Cancer Multidisciplinary Clinic for a second opinion from January 2012 to December 2014.

Methods

Data were collected from patients referred to the Prostate Cancer Multidisciplinary Clinic at Albert Einstein Israeli Hospital whose biopsy specimens underwent pathology review with a dedicated urologic pathologist. Patient data and test results were obtained from scanned institutional records.

After comparing pathological results, we evaluated the medical management after review. Only cases of adenocarcinoma of the prostate were evaluated. For cases in which prostatectomy was performed, we evaluated the Gleason score obtained from surgical specimens for simple conference. Specimens were reviewed by our pathology staff.

Because a new prostate cancer grading system was recently proposed,¹³,¹⁴ we added the new classification (Appendix 1). This project was approved by the institutional review board at Hospital Israelita Albert Einstein (CAAE: 64147617.1.0000.0071).

Results

From January 2012 to December 2014, 50 second-opinion consultations were held at the Prostate Cancer Clinic. A total
of 23 cases of prostate adenocarcinoma had slides for review. These are the subjects of our research.

Patient characteristics are shown in Table 1. The median age was 63 years, and all patients had a Karnofsky performance score of 90% to 100%. The median PSA level was 6.23 ng/mL. Most patients had a T1c or T2a clinical stage.

We found 8 Gleason score changes, corresponding to 34.7% of the sample. The difference in score influenced the treatment in 5 of 8 cases (62.5%) (Appendix 2). After review, the first patient, aged 63 years, PSA of 6.23 ng/mL, and T2a stage with Gleason score 7 (4 + 3) (grade group 3), was upgraded to a Gleason score of 8 (4 + 4) (grade group 4). The other reported patients had a Gleason score of 6 (3 + 3) (grade group 1) that after review had increased to 7 (3 + 4) (grade group 2). Prostatectomy was performed in 4 of them (Table 2).

**Table 1.** Demographic characteristics.

| CHARACTERISTICS | N (23) |
|----------------|-------|
| Age, y         |       |
| Median         | 63    |
| Interval       | 46–74 |
| PSA, ng/mL     |       |
| Median         | 6.23  |
| Interval       | 1.04–13.6 |
| Staging (TNM)  |       |
| T1a            | 2     |
| T1b            | 1     |
| T1c            | 11    |
| T2a            | 5     |
| T2b            | 1     |
| T2c            | 1     |
| T3a            | 1     |
| T4             | 1     |

**Discussion**

Our study shows the importance of pathology review by an expert pathologist in the diagnosis of localized prostate cancer. Gleason score can change in more than one-third of patients and can affect treatment decision in almost two-thirds of reclassified patients.

The use of Gleason score in risk stratification for treatment of prostate adenocarcinoma is well established. The different ways of calculating the score are factors that may result in discordant analysis between pathologists from different services, according to the protocol of each institution.

Currently, the modified Gleason score (International Society of Urological Pathology) makes the standard definition of Gleason pattern 3 extremely rigorous and has led to a reduction in the frequency of Gleason 6 (3 + 3) prostate adenocarcinoma and an increase in the frequency of Gleason 7 (3 + 4).

In other words, a Gleason score of 6 has become a diagnosis of exclusion. Thus, the nonrecognition of new standards for defining criteria of Gleason patterns 3 and 4 (Figure 1) can lead to an “upgrade” at the time of histopathology review in reference centers. Another pathological factor contributing to the discrepancy in Gleason grading between primary centers and referral centers is the low frequency with which Gleason pattern 5 is recognized in prostate biopsy specimens (Figure 2).

According to the series of Fajardo et al, of the total number of cases that were referred for second opinion in a reference center and featured Gleason pattern 5 on biopsy, about 48% had not been identified by general pathologists in the initial stages.

**Table 2.** Discordant cases with histopathologic analysis and established treatments.

| PATIENT NO. | AGE, y | cTNM | PSA, NG/DL | GLEASON (GRADE GROUP) | GLEASON REVISED (GRADE GROUP) | TREATMENT DOUBT | ESTABLISHED TREATMENT |
|-------------|--------|------|------------|-----------------------|-------------------------------|----------------|-----------------------|
| 1           | 63     | T2a  | 6.23       | 7 (4 + 3) [3]         | 8 (4 + 4) [4]                 | Radiotherapy and hormonal blockade or prostatectomy | Prostatectomy  |
| 2           | 71     | T2a  | 7.0        | 6 (3 + 3) [1]         | 7 (3 + 4) [2]                 | Active surveillance or prostatectomy | Prostatectomy  |
| 3           | 55     | T1c  | 11.5       | 6 (3 + 3) [1]         | 7 (3 + 4) [2]                 | Radiotherapy and hormonal blockade or prostatectomy | Radiotherapy and hormonal blockade |
| 4           | 58     | T1b  | 8.6        | 6 (3 + 3) [1]         | 7 (3 + 4) [2]                 | Active surveillance or prostatectomy | Prostatectomy  |
| 5           | 68     | T1c  | 8.84       | 6 (3 + 3) [1]         | 7 (3 + 4) [2]                 | Active surveillance or prostatectomy | Prostatectomy  |

Abbreviations: PSA, prostate-specific antigen; cTNM, clinical tumor, node, metastasis.
The pathology analysis is also directly related to the amount and size of biopsied fragments. It has been demonstrated that the collection of more fragments as well as the greatest extent of fragment increases the diagnostic accuracy.\textsuperscript{20} Even with these details, the Gleason score remains an important risk marker for the disease, mainly because of its strong association with development and prognosis.\textsuperscript{21}

Pathology review is a method used to adjust the real risk of the patient, and it also presents benefits in the case of a confirmed Gleason 6; it allows such patients to be categorized as low risk and permits the choice of an active surveillance strategy.\textsuperscript{22}

## Conclusions

This study demonstrates the need for pathology review in patients with localized prostate cancer before initial treatment; this review can affect treatment decision in almost two-thirds of the recategorized patients. Limitations of our study include limited sample size and retrospective nature of data collection, but the findings echo those of studies from other institutions.\textsuperscript{23,24}

## Author Contributions

All the authors contributed equally to the development of the study.

## References

1. Steyerberg EW, Roobol MJ, Kattan MW, Van der Kwast T, De Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007;177:107–112.

2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149.

3. Rodrigues G, Warde P, Pickles T, et al. Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J. 2012;6:121–127.

4. D’Amico AV, Whittington R, Malkowics SB, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000;55:572–577.

5. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Canc Inst. 1998;90:766–771.

6. Mohler JL. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.

7. Graham J, Baker M, Macherth F, Tininhall V. Guidelines: diagnosis and treatment of prostate cancer: summary of NICE guidance. Br Med J. 2008;336:610–612.

8. Horwich A, Parker C, De Reijke T, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:106–114.

9. Thompson I, Thrasher JR, Aus G, et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131.

10. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.

11. Fleisher NE, Cookson MS, Soloway SM, Fair WR. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998;52:659–662.

12. Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol. 2004;172:98–102.

13. Epstein JI, Egevad L, Amin MB, Delaughter B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–252.
14. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428–435.
15. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;56:823–827.
16. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228–1242.
17. Dong F, Wang C, Farris AB, et al. Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol. 2012;36:838–843.
18. Fajardo DA, Miyamoto H, Miller JS, Lee TK, Epstein JI. Identification of Gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology. Am J Surg Pathol. 2011;35:1706–1711.
19. Al-Hussain TO, Nagar MS, Epstein JI. Gleason pattern 5 is frequently underdiagnosed on prostate needle-core biopsy. Urology. 2012;79:178–181.
20. King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Canc. 2000;90:326–330.
21. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;277:1445–1451.
22. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23:8165–8169.
23. Laramore GE, Zeng J, Fang LMC, Liao JJ, Russell KJ. Pathology review for patients with prostate cancer referred to the SCCA proton center. Int J Part Ther. 2015;1:878–883.
24. Townsend NC, Ruth K, Al-Saleem T, et al. Gleason scoring at a comprehensive cancer center: what’s the difference? J Natl Compr Canc Netw. 2013;11:812–819.

Appendix 1. New grading system.

| TRADITIONAL GLEASON SCORE | NEW GRADING SCORE |
|---------------------------|-------------------|
| Gleason score ≤6          | Grade group 1     |
| Gleason score 3+4 = 7     | Grade group 2     |
| Gleason score 4+3 = 7     | Grade group 3     |
| Gleason score 8           | Grade group 4     |
| Gleason score 9–10        | Grade group 5     |

Appendix 2. Histopathological evaluation.

| Cases   | 23 |
|---------|----|
| Concordant Gleason | 15 |
| 6 (GG 1) | 12 |
| 7 (GG 2–3) | 2 |
| 8 (GG 4) | 1 |
| Discordant Gleason | 8 |
| Increase score | 7 |
| 6 → 7 (GG 1 → GG 2) | 5 |
| 7 → 8 (GG 3 → GG 4) | 1 |
| 7 → 9 (GG 3 → GG 5) | 1 |
| Decrease score | 1 |
| 9 → 8 (GG 5 → GG 4) | 1 |

Abbreviation: GG, grade group.